<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637168</url>
  </required_header>
  <id_info>
    <org_study_id>GGKEMS0910</org_study_id>
    <nct_id>NCT01637168</nct_id>
  </id_info>
  <brief_title>Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders</brief_title>
  <official_title>Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two different drugs in&#xD;
      the treatment of patients diagnosed with memory difficulties and a decline in cognitive&#xD;
      function.&#xD;
&#xD;
      This is a parallel distribution: a group of patients will be treated with a combination Panax&#xD;
      Ginseng + Ginkgo Biloba + multivitamin + Polyminerals (EMS), and another group with Ginkgo&#xD;
      Biloba (Tebonin ®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
        -  multicenter, phase III, double-blind, randomized entry of patients, prospective and&#xD;
           comparative&#xD;
&#xD;
        -  The duration of the study: 60 days&#xD;
&#xD;
        -  3 visits (days 1, 30 and 60)&#xD;
&#xD;
        -  Evaluate the effectiveness of the association&#xD;
&#xD;
        -  Evaluate the safety of the combination&#xD;
&#xD;
        -  Adverse events evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Canceled [By sponsor decision)&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study to evaluate the efficacy and safety of the association Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamins compared to Ginkgo Biloba (Tebonin ®) for the symptomatic treatment of disorders of cognitive function.</measure>
    <time_frame>60 days</time_frame>
    <description>To evaluate the efficacy of the association between Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin to treat patients with disorders of cognitive function compared to treatment with the drug Ginkgo Biloba (Tebonin ®)&#xD;
The assessment of effectiveness will be determined by statistical evaluation of the scores of responses related to quality of life questionnaires and psychometric tests (Mini-Mental Test and Test of Logical Memory WMS-R).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study to evaluate the efficacy and safety of the association Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamins compared to Ginkgo Biloba (Tebonin ®) for the symptomatic treatment of disorders of cognitive function.</measure>
    <time_frame>60 days</time_frame>
    <description>To evaluate the safety of the association between Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin to treat patients with disorders of cognitive function compared to treatment with the drug Ginkgo Biloba (Tebonin ®).&#xD;
The safety of the medication to be prescribed by the observation of adverse events and related to the study medication. Analysis of safety tests (biochemical profile, complete blood count, blood glucose, cholesterol and uric acid) requested at visit 1 and 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Memory Deficit</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin</intervention_name>
    <description>A tablet, 2 times daily (12/12 hours).</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo Biloba (Tebonin®)</intervention_name>
    <description>A tablet, 2 times daily (12/12 hours).</description>
    <arm_group_label>Comparator Group</arm_group_label>
    <other_name>Ginkgo Biloba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of any race, sex, aged 18-60 years;&#xD;
&#xD;
          2. Patients presenting two or more symptoms associated with disorders of cognitive&#xD;
             function such as memory impairment, poor concentration, depressed mood, decreased&#xD;
             mental capacity, provided they score value is below 24 in the evaluation of the&#xD;
             psychometric test (Mini Test-mental and WMS-R Logical Memory);&#xD;
&#xD;
          3. Consent of the patient (Signature of the IC);&#xD;
&#xD;
          4. Patients are able to read and write;&#xD;
&#xD;
          5. &quot;Washout&quot; of at least two weeks of the start of the study, in case of use of&#xD;
             multivitamins or any other medication for symptomatic treatment of disorders of&#xD;
             cognitive function.&#xD;
&#xD;
          6. Women of childbearing potential must submit βHCG negative serum;&#xD;
&#xD;
          7. Patients are able to understand and carry out the study procedures;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hypersensitivity to the components of the formula;&#xD;
&#xD;
          2. Patients who are making use of levodopa or salicylates;&#xD;
&#xD;
          3. Routine use of medications that alter cognitive functions such as barbiturates,&#xD;
             anticonvulsants, benzodiazepines, neuroleptics, alcohol and illicit drugs;&#xD;
&#xD;
          4. Pregnant or lactating women;&#xD;
&#xD;
          5. Participation in another clinical trial with investigational medication in the last 3&#xD;
             months;&#xD;
&#xD;
          6. Patients with prior knowledge of infectious disease;&#xD;
&#xD;
          7. Patients who are taking other multivitamins or any other medications for the&#xD;
             symptomatic treatment of disorders of cognitive function, at least two weeks prior to&#xD;
             study initiation.&#xD;
&#xD;
          8. Patients with organic dementias such as Alzheimer's, Pick's disease, Creutzfeldt-Jacob&#xD;
             Disease, Huntington's, Parkinson's disease, dementia caused by human immunodeficiency&#xD;
             virus (HIV), hypothyroidism, vascular dementia (arteriosclerotic dementia), dementia&#xD;
             senile among others;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felício MD Savioli Neto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Dr. Felício Savioli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliníca Dr. Felício Savioli</name>
      <address>
        <city>Cotia</city>
        <state>São Paulo</state>
        <zip>06710-670</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disorders of cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

